CareDx Inc (CDNA)

Official site

HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

$78.56

+2.23 (+2.92%)

Market Cap: $4.51B

Last updated: Nov 06, 2026 at 4:20 PM ET

Earnings

Performance (10Y)

Beat Rate

78%(31/40)

Avg Surprise

+150.43%

Streak

5 Q

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$1.18

Range$1.15 - $1.21

4 analysts

Revenue Consensus

$174M

Range$154M - $185M

6 analysts

Period ending Mar 31, 2027

EPS Consensus$0.30

Range$0.21 - $0.37

6 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$0.27+11.3%

60d ago$0.30+0.4%

30d ago$0.25+20.4%

7d ago$0.25+20.4%

Current$0.30

Revenue Consensus

$129M

Range$123M - $134M

7 analysts

Last 12 of 40 reported quarters and 2 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Mar 31, 2027Mar 27EST	-	$0.30	$0.21 - $0.37	-	-	6	4 0 30d	-
Dec 31, 2026Dec 26EST	-	$1.18	$1.15 - $1.21	-	-	4	-	-
Sep 30, 2026Sep 26 Reported Oct 29, 2026Reported Oct 29	$0.52	$0.07	$0.05 - $0.09	+642.86%	Beat	6	5 0 30d	+85.7%
Jun 30, 2026Jun 26 Reported Jul 30, 2026Reported Jul 30	$0.17	$0.06	$0.03 - $0.10	+183.33%	Beat	5	1 0 30d	+70.0%
Mar 31, 2026Mar 26 Reported Apr 28, 2026Reported Apr 28	$0.34	$0.13	$0.11 - $0.15	+161.54%	Beat	5	0 4 30d	+240.0%
Dec 31, 2025Dec 25 Reported Feb 24, 2026Reported Feb 24	$0.12	$-0.01	$-0.03 - $0.00	+1300.00%	Beat	6	1 0 30d	-33.3%
Sep 30, 2025Sep 25 Reported Nov 4, 2025Reported Nov 4	$0.28	$0.14	$0.12 - $0.17	+100.00%	Beat	6	1 3 30d	+100.0%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$0.10	$0.12	$0.10 - $0.14	-16.67%	Miss	5	1 4 30d	-60.0%
Mar 31, 2025Mar 25 Reported Apr 30, 2025Reported Apr 30	$0.10	$0.07	$0.06 - $0.09	+42.86%	Beat	6	1 3 30d	+433.3%
Dec 31, 2024Dec 24 Reported Feb 26, 2025Reported Feb 26	$0.18	$0.15	$0.07 - $0.18	+22.03%	Beat	4	2 0 30d	+205.9%
Sep 30, 2024Sep 24 Reported Nov 4, 2024Reported Nov 4	$0.14	$0.01	$-0.02 - $0.06	+1300.00%	Beat	6	3 0 30d	+177.8%
Jun 30, 2024Jun 24 Reported Jul 31, 2024Reported Jul 31	$0.25	$-0.14	$-0.21 - $-0.12	+278.57%	Beat	5	1 0 30d	+238.9%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.03	N/A	-	+85.71%	Beat	5	0 1 30d	+72.7%
Dec 31, 2023Dec 23 Reported Feb 28, 2024Reported Feb 28	$-0.17	$-0.27	$-0.29 - $-0.24	+37.04%	Beat	5	1 0 30d	-142.9%

Key Metrics

Valuation
P/E Ratio	68.31	EV/EBITDA	28.07x
Price/FCF	47.74x	FCF Yield	2.09%
Profitability
Profit Margin	25.90%	Operating Margin	8.48%
ROE	33.00%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	4.58x	Quick Ratio	4.51x
Trading Statistics
Beta	2.49	Avg Volume	1.42M
52-Week High	$90.87	52-Week Low	$15.15

Technical Indicators Dashboard

Moving Averages

SMA 10$78.58

SMA 20$72.75

SMA 50$63.23

SMA 200$35.20

EMA 10$78.55

EMA 20$74.25

EMA 50$64.75

EMA 200$41.67

MACD

Line: 5.58Signal: 5.19Hist: 0.39

ADX

ADX: 51.6+DI: 27.1-DI: 14.8

Aroon & PSAR

Aroon Up80.0

Aroon Down16.0

PSAR$73.58

Bollinger Bands

Upper Band$89.12

Lower Band$56.39

%B Position4498%(Upper)

Band Width0.68

RSI (14-Day)

Neutral

59.1

Momentum Oscillators

Stoch %K59.2

Stoch %D72.5

Williams %R-49.3

ROC (10d)13.5%

Momentum9.35

CCI (20d)55.9

MFI (14d)51.4

Volatility Measures

ATR (14d)$5.38(6.9%)

StdDev (20d)8.18

Hist Vol97.1%(High)

Volume Flow

VWAP$78.35

OBV59.7M

AD Line18.6M

CMF (20d)0.034

Volume Metrics

Avg Vol (20d)1.4M

Vol Ratio0.8x

VWMA (20d)$74.93

Pivot Points

R3$89.14

R2$86.37

R1$81.35

Pivot Point$78.58

S1$73.56

S2$70.79

S3$65.77

Advanced Oscillators

TSI35.06

Ultimate Osc53.6

KST284.46

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$263.90M	$117.70M	$108.39M	$100.06M	$86.68M	$84.69M	$86.58M	$82.88M	$92.27M	$72.05M	$65.57M	$67.19M
Cost of Revenue	$34.97M	$33.63M	$35.51M	$30.65M	$28.66M	$28.41M	$28.19M	$27.57M	$28.00M	$25.93M	$25.68M	$24.53M
Gross Profit	$228.93M	$84.07M	$72.87M	$69.40M	$58.02M	$56.27M	$58.39M	$55.31M	$64.28M	$46.12M	$39.89M	$42.66M

Operating Expenses	$115.45M	$82.87M	$78.91M	$69.65M	$69.14M	$69.64M	$-25,991,000	$69.03M	$71.60M	$68.68M	$162.52M	$71.44M
R&D	$22.38M	$21.42M	$19.31M	$16.77M	$16.83M	$18.52M	$16.62M	$17.49M	$19.69M	$18.71M	$18.83M	$19.00M
SG&A	$40.91M	$30.48M	$28.68M	$28.43M	$27.68M	$22.77M	$32.35M	$31.74M	$30.91M	$30.14M	$27.51M	$33.97M
Operating Income	$113.22M	$1.20M	$-6,040,000	$-246,000	$-11,121,000	$-13,374,000	$84.38M	$-13,721,000	$-7,327,000	$-22,566,000	$-122,632,000	$-28,783,000

Interest Income	$1.74M	$1.91M	$2.01M	$2.01M	$2.36M	$2.78M	$3.05M	$3.00M	$2.83M	$2.88M	$3.16M	$3.17M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$114.52M	$2.78M	$-3,763,000	$1.66M	$-8,685,000	$-10,295,000	$87.87M	$-10,437,000	$-4,601,000	$-19,971,000	$-117,932,000	$-23,565,000
Income Tax Expense	$3.88M	$-32,012	$345,000	$-15,000	$-117,000	$58,000	$171,000	$200,000	$22,000	$-83,000	$165,000	$-80,000

Net Income	$110.64M	$2.81M	$-4,108,000	$1.68M	$-8,568,000	$-10,353,000	$87.70M	$-10,637,000	$-4,623,000	$-19,888,000	$-118,097,000	$-23,485,000

EBITDA	$118.63M	$7.10M	$-736,000	$5.74M	$-6,271,000	$-7,302,000	$88.95M	$-8,193,000	$-3,100,000	$-16,182,000	$-117,559,000	$-23,025,000
EBIT	$114.08M	$868,000	$-5,776,000	$-353,000	$-11,049,000	$-13,079,000	$84.81M	$-13,438,000	$-7,427,000	$-22,856,000	$-121,091,000	$-26,736,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CDNA

Government Contracts

Gov Obligations (TTM)

$4.45M

Gov Obligations / Revenue

1.0%

Obligations YoY

24.2%

Active Awards

New Awards (TTM)

Avg Remaining Term

7.9 mo

Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
36C25226N0079	Department of Veterans AffairsDepartment of Veterans Affairs	$1.60M	Feb 1, 2026	Jan 31, 2027	TRANSPLANT TESTING KITS
36C24926N0622	Department of Veterans AffairsDepartment of Veterans Affairs	$1.05M	Sep 23, 2026	Sep 22, 2027	GENETIC BLOOD TESTING FOR TRANSPLANT PATIENTS (ALLOMAP AND ALLOSURE)
36C25225N0531	Department of Veterans AffairsDepartment of Veterans Affairs	$849384	Sep 30, 2025	Feb 28, 2026	TRANSPLANT TESTING KITS
36C25626N0370	Department of Veterans AffairsDepartment of Veterans Affairs	$770805	Apr 1, 2026	Mar 31, 2027	LAB TESTS FOR POST TRANSPLANT CARE.
36C26326N0261	Department of Veterans AffairsDepartment of Veterans Affairs	$142038	Jan 15, 2026	Jan 14, 2027	ALLOSURE IN-HOME PATIENT TESTING

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

Cathie Wood’s ARK sells CareDx stock, buys Natera and Kratos

Cathie Wood's ARK ETFs executed several trades on November 6, 2026, selling 113,168 shares of CareDx, Inc. (CDNA) for over $8.6 million. Simultaneously, ARK made significant purchases, acquiring 61,961 shares of Natera...

Investing.com•Nov 6, 2026 8:54 PM ET11/6/26•Bearish

58,713 option shares are part of a CareDx (CDNA) officer's proposed stock sale.

CareDx (CDNA) officer Keith S. Kennedy has filed notice for a proposed sale of 79,243 common shares, valued at an aggregate market value of $6,803,803.98. This sale includes 58,713 shares expected from stock-option...

Stock Titan•Nov 5, 2026 9:54 PM ET11/5/26•Somewhat-Bearish

Form 4 Caredx Inc: Jeffrey Adam Novack (Secretary and General Counsel) For: 1 November By Investing.com

This article reports on a Form 4 filing for CareDx Inc. indicating an insider transaction by Jeffrey Adam Novack...

Investing.com India•Nov 3, 2026 8:42 PM ET11/3/26•Neutral

Form 4 Caredx Inc: Jeffrey Adam Novack (Secretary and General Counsel) For: 1 November

This article reports on a Form 4 filing for CareDx Inc. It details that Jeffrey Adam Novack, Secretary and General Counsel of CareDx Inc....

Investing.com Canada•Nov 3, 2026 8:11 PM ET11/3/26•Neutral

Counsel retains 102,205 shares after CareDx (CDNA) withholds 2,873 shares for taxes.

CareDx, Inc. (CDNA) withheld 2,873 shares from Secretary and General Counsel Jeffrey Adam Novack on November 1, 2026...

Stock Titan•Nov 3, 2026 8:11 PM ET11/3/26•Neutral

CDNA Valuation and Fair Value

P/E: 68.3x
Forward P/E: 137.0x
EV/EBITDA: 28.1x
P/FCF: 47.7x
PEG: -0.1x
P/B: 9.5x

See GNG's fair value

CDNA Profitability: Margins, ROIC and FCF

Gross margin: 77.2%
Operating margin: 8.5%
Net margin: 25.9%
ROE: 33.0%
FCF yield: 2.1%

CDNA Competitors

Company	Ticker
Heartflow, Inc. Common Stock	HTFL
Akero Therapeutics Inc	AKRO
Sotera Health Co	SHC
iRhythm Technologies Inc	IRTC
Dianthus Therapeutics Inc.	DNTH
Legend Biotech Corp	LEGN
Amicus Therapeutics Inc	FOLD
Integer Holdings Corp	ITGR

Sector: Healthcare

CDNA Analyst Ratings

Consensus: Buy
Analysts: 7
Strong Buy: 0
Buy: 5
Hold: 2
Sell: 0
Strong Sell: 0

CDNA Bull Case vs Bear Case

Bull case

CDNA has a 25.9% net profit margin.
CDNA beat EPS estimates in 87.5% of its last 8 reported quarters.
CDNA grew quarterly revenue 39.3% year over year.

Bear case

CDNA trades at 68.3x trailing earnings.

CDNA Earnings: Beat Rate and Next Report

Beat rate: 7 of 8 quarters (87.5%)
Average surprise: 304.5%
EPS estimate (fiscal period ending Dec 31, 2026): $1.18

CDNA Earnings Date

CDNA reports Feb 22, 2027, after the close. The date is estimated.

CDNA Earnings Call

The latest CDNA earnings call transcript on file is labeled 2026Q3.

Read the 2026Q3 transcript

CDNA ETF Holders

GNG tracks 16 ETFs that hold CDNA. The largest weights:

Innovator IBD 50 ETF (FFTY), 3.67% of the fund
ARK Genomic Revolution ETF (ARKG), 3.55% of the fund
State Street SPDR S&P Biotech ETF (XBI), 0.93% of the fund
First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.69% of the fund
Fidelity Enhanced Small Cap Core ETF (FESM), 0.23% of the fund

Open the ETF Stock Exposure tool for CDNA

See insider activity

Frequently Asked Questions About CDNA

When does CDNA report earnings?

CareDx Inc (CDNA) is expected to report earnings on Feb 22, 2027.

Does CDNA pay dividends?

CareDx Inc (CDNA) does not currently pay a regular dividend.

What is CDNA's P/E ratio?

CareDx Inc has a price-to-earnings (P/E) ratio of 68.31.

What is CDNA's market cap?

CareDx Inc (CDNA) has a market capitalization of $4.51B with a current stock price of $78.56.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In